ICAD Icad Dashboard

iCAD, Inc. is a medical technology company, which engages in the provision cancer detection and therapy solutions. It operates through the Cancer Detection and Cancer Therapy segments. The Cancer Detection segment include image analysis and workflow products. The Cancer Therapy segment consists radiation therapy products. The company was founded in 1984 and is headquartered in Nashua, NH.

Company profile

Ticker

ICAD

Exchange

NASDAQ

Website

www.icadmed.com

CEO

Michael S. Klein

Incorporated

Delaware

Location

New Hampshire

Fiscal year end

Dec 31

Sector

Manufacturing > Small Arms, Ordnance, and Ordnance Accessories Manufacturing

Industry (SIC)

Surgical & Medical Instruments & Apparatus

Boston Scientific • Baxter International • Becton, Dickinson And • 3M • Stryker • Teleflex • Resmed • Hill-Rom • Integra Lifesciences • Nuvasive ...

Former names

HOWTEK INC

SEC CIK

0000749660

Corporate docs

Articles of Incorporation & Bylaws

IRS number

20377419

ICAD stock data

S&P 500

1M 1Y 2Y 5Y

News

Pro users get this 30m faster

iCAD Highlights Presentation Of Data At Society Of Breast Imaging Symposium Apr. 9-11 And National Consortium Of Breast Centers Annual Interdisciplinary Breast Center Conference Apr. 16-19

19 Apr 21

iCAD, Inc. (NASDAQ:ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that new research supporting the clinical value of ProFound AI® for

Stocks That Hit 52-Week Highs On Thursday

1 Apr 21

During Thursday's morning session, 164 companies made new 52-week highs.

iCad Highlights Retrospective Analysis That Co's ProFound AI For 2D Mammography Might 'Notably Reduce The Risk Of Interval Breast Cancer'

31 Mar 21

iCAD, Inc. (NASDAQ:ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that ProFound® AI for 2D Mammography might notably reduce

ICAD Focuses On Areas Of High Unmet Need In Cancer Detection, BTIG Says

23 Mar 21

Benzinga's Top Ratings Upgrades, Downgrades For March 23, 2021

23 Mar 21

Press releases

Pro users get this 30m faster

iCAD to Report First Quarter 2021 Financial Results on Wednesday, April 28

20 Apr 21

NASHUA, N.H., April 20, 2021 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ:ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that it will release financial

New Research Confirms iCAD's ProFound AI Aids Breast Cancer Detection with Digital Breast Tomosynthesis, Improves Radiologists' Workflow

19 Apr 21

NASHUA, N.H., April 19, 2021 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ:ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that new research supporting

iCAD Announces Estimated Q1 Revenues and Upcoming CFO Transition

5 Apr 21

Company expects preliminary estimated revenues to exceed $8.1 million Successor CFO search underway NASHUA, N.H., April 05, 2021 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ:ICAD), a global medical technology leader

iCAD Announces FDA Clearance for ProFound AI Version 3.0 for 3D Mammography

15 Mar 21

New Research Supporting ProFound AI Presented at European Congress of Radiology Online Meeting

8 Mar 21

Investment data

Data from SEC filings

Securities sold

Number of investors

Calendar

15 Mar 21

21 Apr 21

31 Dec 21

Financial summary

Financial statements Chart ICAD financial data

Quarter (USD)	Dec 20	Sep 20	Jun 20	Mar 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 20	Dec 19	Dec 18	Dec 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from Icad earnings reports.

Cash burn rate (estimated)	Burn method: Change in cash		Burn method: Operating income/loss		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	27.19M	27.19M	27.19M	27.19M	27.19M	27.19M
Cash burn (monthly)	(positive/no burn)	(positive/no burn)	533K	1.46M	300.67K	582.08K
Cash used (since last report)	n/a	n/a	1.97M	5.42M	1.11M	2.15M
Cash remaining	n/a	n/a	25.21M	21.77M	26.07M	25.03M
Runway (months of cash)	n/a	n/a	47.3	14.9	86.7	43.0

Beta Read what these cash burn values mean

Recent insider trades

ICAD insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
15 Feb 21	Klein Michael S	Stock Option Common Stock	Grant	Aquire A	No	No	18	76,982	1.39M	76,982
15 Feb 21	Go Jonathan	Stock Option Common Stock	Grant	Aquire A	No	No	18	24,286	437.15K	24,286
15 Feb 21	Areglado R. Scott	Stock Option Common Stock	Grant	Aquire A	No	No	18	23,689	426.4K	23,689
15 Feb 21	Stevens Stacey M	Stock Option Common Stock	Grant	Aquire A	No	No	18	33,981	611.66K	33,981
15 Feb 21	Sassine Andy	Common Stock	Grant	Aquire A	No	No	0	3,500	0	1,318,382
15 Feb 21	Sassine Andy	Stock Option Common Stock	Grant	Aquire A	No	No	18	30,000	540K	30,000

Data from 3, 4 and 5 filings. Stock values as filed, not updated for current price.

Institutional ownership Q4 2020

ICAD institutional ownership history Ownership history

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

43.2% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	81	79	+2.5%
Opened positions	8	11	-27.3%
Closed positions	6	17	-64.7%
Increased positions	29	30	-3.3%
Reduced positions	35	24	+45.8%

13F shares	Current	Prev Q	Change
Total value	664.35M	135.33M	+390.9%
Total shares	10.77M	9.93M	+8.5%
Total puts	0	16.3K	EXIT
Total calls	85.5K	85.4K	+0.1%
Total put/call ratio	–	0.2	–

Largest owners	Shares	Value	Change
BLK Blackrock	1.45M	$19.17M	+3.1%
Portolan Capital Management	1.16M	$15.33M	+138.0%
Vanguard	1.07M	$14.18M	+1.2%
G2 Investment Partners Management	885.37K	$11.69M	-20.0%
FHI Federated Hermes	649.55K	$8.57M	0.0%
Parkman Healthcare Partners	542.6K	$7.16M	-6.7%
Wellington Management	456.7K	$6.03M	+48.6%
STT State Street	336.13K	$4.44M	+13.2%
Geode Capital Management	311.12K	$4.11M	+3.3%
Renaissance Technologies	260.59K	$3.44M	-31.7%

Largest transactions	Shares	Bought/sold	Change
Portolan Capital Management	1.16M	+673.28K	+138.0%
Schonfeld Strategic Advisors	110.7K	-227.3K	-67.2%
G2 Investment Partners Management	885.37K	-221.01K	-20.0%
DB Deutsche Bank AG - Registered Shares	192.63K	+181.38K	+1611.5%
Granite Point Capital Management	178.57K	+178.57K	NEW
Wellington Management	456.7K	+149.3K	+48.6%
Renaissance Technologies	260.59K	-120.98K	-31.7%
Essex Investment Management	113.4K	+113.4K	NEW
Russell Investments	260.21K	+103.82K	+66.4%
Millrace Asset	45.97K	-95.43K	-67.5%

Data from 13F filings. Stock values as filed, not updated for current price. Long positions only.

Financial report summary

Competition

Varian Medical Systems • Hologic • Sensus Healthcare

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. freshman Avg

New words: Alliance, alter, ATM, Bangladesh, benchmark, Biden, brokerage, cancelling, capacity, carefully, deduced, detector, distancing, dosage, dosimetric, duration, ease, Edition, encouraging, Ewing, feasible, felt, flat, foremost, fuller, Germany, gradual, Guggenheim, hosting, incentivizing, inline, Institutet, Interbank, issuedASU, JMP, Kesari, lender, LIBOR, makea, motivate, nationwide, nearby, noncompliance, notice, onset, outpatient, pandemic, partly, printed, prompted, radiochromic, referenced, requisite, resurgence, reward, risky, RO, Santosh, scalability, social, stone, stream, succeed, supposed, SVB, switch, Therapixel, tied, transformation, unaccrued, underwent, unprecedented, vacation, vivo, waiver, Wall, worsening, wrote

Removed: accrual, accrue, Acorn, acumen, adherence, age, agent, Andy, anniversary, annum, assetor, attachment, Bachelor, back, BESP, biopharma, Bird, borrow, borrowed, burn, CADx, caption, chair, charter, Christopher, Clarke, collectability, commitment, concluding, confidence, consistency, constituted, CRA, deficiency, deliverable, description, determinable, discontinuance, discontinue, dissolved, division, Dr, drawn, driver, earliest, EBITDA, effected, escrow, ethical, ExBRT, exceeding, excise, excluding, existed, expert, expertise, Fidelity, Fleet, floating, focusing, forfeiture, franchise, Freedom, gain, Gemphire, Harvard, Hearing, honesty, indefinite, Insider, Iowa, Jeffrey, joining, Kenneth, knowledge, leader, led, liable, manager, mature, MBA, Meditech, Mexico, modifying, MYnd, ninety, Nominating, noted, objective, occasion, occupation, Pennsylvania, persuasive, plea, postponement, president, pursue, Ratification, registration, Revolution, safely, Sassine, Science, Secretary, server, sound, Speech, subsidize, superseded, surrendered, suspended, taxing, Tippie, TPE, trailing, twelve, ultrasound, unaudited, upcoming, vice, VSOE, Wharton, woman, writing, XAC

From filing 10-K 2020 FY